Proposal No. **17-106**

Proposal for Task Force Consideration at the ISSC 2019 Biennial Meeting	a. ☒ Growing Area b. ☐ Harvesting/Handling/Distribution c. ☐ Administrative

Submitter	Pacific Rim Shellfish Sanitation Association
Affiliation	Sitka Tribe of Alaska
Address Line 1	456 Katlian St
Address Line 2	
City, State, Zip	Sitka, AK 99835
Phone	907-747-7356
Fax	907-747-4915
Email	michael,jamros@sitkatribe-nsn.gov
Proposal Subject	Matrix Expansion for the Receptor Binding Assay (RBA) for Paralytic Shellfish Poisoning (PSP) Toxicity Determination to Allow Use with Geoduck
Specific NSSP Guide Reference	Section IV, Chapter II.14 -- NSSP Approved Laboratory Tests (p. 261 Table 2. Approved Methods for Marine Biotoxin Testing -- footnote 2, and/or p. 263 Table 4. Limited Use Methods for Marine Biotoxin Testing -- footnote 5)
Text of Proposal/ Requested Action	This submission presents the 'Matrix Expansion for the Receptor Binding Assay (RBA) for Paralytic Shellfish Poisoning (PSP) Toxicity Determination to Allow Use with Geoduck' for consideration as an NSSP Approved Method for Marine Biotoxin Testing for PSP in Geoduck. The RBA is a competition-based assay that employs radiolabeled saxitoxin (3H-STX) to compete with PSP toxins present in standards/samples for binding sites on natural receptors in the assay. Following incubation with the receptors, unbound 3H-STX is removed and the remaining labeled toxin is measured with a scintillation counter. The amount of remaining 3H-STX is inversely proportional to standard/sample toxicity. The RBA offers a high-throughput, sensitive, and quantitative alternative to the mouse bioassay (MBA), which has been the long-standing reference method for PSP toxicity. Further, the RBA eliminates the use of live animals for detection of these toxins. While the RBA still uses receptors prepared from animals, the number of animals required for analysis is significantly reduced. Using native receptors as the analytical recognition elements for the assay allows for a composite measure of overall toxicity, as opposed to toxin concentrations measured by liquid chromatographic methods that require conversion factors of equivalent toxicity to calculate the overall toxicity. The RBA has undergone AOAC single and multi-laboratory validation and is designated through AOAC as an Official Method of Analysis (OMA 2011.27). The RBA is currently an NSSP Approved Method for Marine Biotoxin Testing for PSP in mussels as well as a NSSP approved for Limited Use Method for clams and scallops for the purpose of screening and precautionary closure for PSP (ISSC 2015 Summary of Actions Proposal 13-114). Here we provided results from a single laboratory validation study for use of RBA with the matrix geoduck (*Panopea*) viscera for submission for the RBA to be considered for approval as an NSSP Approved Method for Marine Biotoxin Testing for PSP.
Public Health Significance	Paralytic shellfish poisoning intoxications result from the consumption of seafood (primarily bivalve molluscs) contaminated with neurotoxins known as paralytic

	shellfish toxins (PSTs). This suite of toxins binds to voltage-gated sodium channels and may result in paralysis if enough toxin is consumed. In extreme cases when respiratory support is not available to the patient, the intoxication may prove fatal. Since the toxins cannot be destroyed during cooking and there is no way to remove the toxins from seafood, the best control strategy is to ensure that contaminated product never reaches the market. To protect public health, harvesting closures are implemented when toxicity exceeds the guidance level of 80 micrograms saxitoxin equivalents per 100 grams of shellfish tissue. As such, accurate analytical methods are needed to monitor shellfish toxicity for making decisions regarding opening and closing shellfish growing areas accordingly. Acceptance of the RBA as an NSSP Approved Method for Marine Biotoxin Testing for PSP toxicity determination in geoduck (*Panopea*) would provide monitoring and management programs with an additional tool that can be used for monitoring toxin levels and making regulatory decisions. Not only does the RBA eliminate the need for live animals for PSP testing, it is also more sensitive than the MBA, thereby providing an early warning system for monitoring programs as toxin levels begin to rise.
Cost Information	For the assay: The estimated cost per 96-well plate assay is ~$95.00. Including standards and samples with triplicate measurements (as well as three dilutions per sample[ranging from 3.5-600 µg STX eq 100 g-1] to ensure the unknown samples fall within linear range of assay), the cost per sample for quantitation would be ~$13.60. If running multiple plates or in screening mode, sample costs would be reduced. (Van Dolah 2013) For proposal: The cost of RBA work for geoduck matrix expansion is covered by and existing grant awarded to the Sitka Tribe of Alaska. Naturally contaminated samples from Washington and Alaska are pulled from regular samples tested by the respective state agencies that are part of routine shellfish testing. Therefore, there is no additional cost or funding necessary for the proposal.
Research Needs Information	
a. Proposed specific research need/ problem to be addressed	Paralytic shellfish poisoning (PSP) is a foodborne illness caused by ingestion of contaminated shellfish. The paralytic shellfish toxin, saxitoxin (STX), and its analogs are potent neurotoxins responsible for PSP. Marine dinoflagellates and freshwater cyanobacteria produce STX. The STX can accumulate in filter-feeding bivalve mollusks to levels that are toxic to humans. Symptoms of PSP include: tingling and numbness of the perioral area and extremities, drowsiness, incoherence, loss of motor control, and following high dose consumption, respiratory paralysis. In 1965 the mouse bioassay (MBA) was adopted as an official AOAC method for STX determination. The MBA has been the only method available for PSP testing for the last five decades. Both North American and European regulatory agencies have expressed the desire to transition to a more humane PSP testing method that does not require the use of live animals and is not subject to the matrix effects documented for the MBA (Turner 2012). Recently, the NSSP approved a post-column oxidation liquid chromatographic (PCOX) method and a receptor binding assay (RBA) as alternatives to the MBA. The PCOX method is approved for full use; whereas, the RBA is approved for limited use (the RBA is only approved for shellfish matrices evaluated in the single lab and multi-lab validation studies). Both the PCOX and RBA are sensitive quantitative assays for STX detection, and

	they do not require the use of live animals. The RBA is approved for regulatory testing of mussels as an alternative to the MBA and is approved for limited use as a screening tool for clams and scallops, but is not yet approved for use with geoduck (*Panopea*) due to a lack of data. Geoduck are a major commercial product, with large dive fisheries in Southeast Alaska and the Puget Sound that require STX testing. This proposal requests consideration for the NSSP RBA approval to be expanded to include geoduck. The proposal provides data from a single laboratory validation (SLV) of the RBA for geoduck testing as support for this request.
b. Explain the relationship between proposed research need and program change recommended in the proposal	This method is intended for use as an NSSP Approved Limited Use Method for screening for PSP toxicity in shellfish. The RBA serves as an alternative to the MBA in these applications, offering a measure of composite toxicity with high throughput and the elimination of live animal testing. (Van Dolah 2013) This application is for the addition of geoduck to the list of matrices approved for use with the RBA. There is an acknowledged need for this method in NSSP. A significant portion of the Washington and Alaska state shellfish industries are comprised of the harvest of geoduck. Approval of the RBA for use with geoduck would provide an alternative to (1) the MBA, which uses live animals, and (2) the PCOX HPLC method, which requires costly equipment and skilled personnel and offers low throughput. Acceptance of the RBA as an NSSP Approved Method for Marine Biotoxin Testing for PSP toxicity determination in geoduck would provide monitoring and management programs with an additional tool that can be used for monitoring toxin levels and making regulatory decisions. Not only does the RBA eliminate the need for live animals for PSP testing, it is also more sensitive than the MBA. **References**: Van Dolah 2013. ISSC application: Receptor Binding Assay (RBA) for Paralytic Shellfish Poisoning (PSP)Toxicity Determination. Van Dolah et al. 2012. Determination of paralytic shellfish toxins in shellfish by receptor binding assay: collaborative study. J AOAC Int. May-Jun;95(3):795-812. Van Dolah et al. 2009. Single-laboratory validation of the microplate receptor binding assay for paralytic shellfish toxins in shellfish. J AOAC Int. Nov-Dec;92(6):1705-13. Ruberu et al. 2012. Evaluation of variability and quality control procedures for a receptor-binding assay for paralytic shellfish poisoning toxins. Food Addit Contam Part A Chem Anal Control Expo Risk Assess.29(11):1770-9. Turner et al. 2012. Investigations into matrix components affecting the performance of the official bioassay reference method for quantitation of paralytic shellfish poisoning toxins in oysters. Toxicon : official journal of the International Society on Toxicology 59, 215-230. OMA 2011.27. AOAC Official Method 2011.27 Paralytic shellfish toxins (PSTs) in

	shellfish, receptor binding assay. In Official Methods of Analysis of AOAC International. http://www.eoma.aoac.org.
c. Estimated cost	
d. Proposed sources of funding	This research was performed by the Sitka Tribe of Alaska using funds from an ANA ERE grant
e. Time frame anticipated	
Action By 2017 Laboratory Committee	Recommended referral to an appropriate committee as determined by the Conference Chair.
Action By 2017 Task Force I	Recommended adoption of the Laboratory Committee recommendation on Proposal 17-106.
Action by 2017 General Assembly	Adopted the recommendation of Task Force I on Proposal 17-106.
Action by FDA February 7, 2018	Concurred with Conference action on Proposal 17-106.